Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Van Neste, Leander" or (type any "bookEditor issueEditor" and editor="Van Neste, Leander")

Add to list
- Journal Article
- A1
- open access
Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men

Robert L, Jr Waterhouse, Leander Van Neste, Kelvin A Moses, Carlton Barnswell, Jonathan L Silberstein, Mark Jalkut, Ronald Tutrone, James Sylora, Ronald Anglade, Myron Murdock, et al.

(2019) UROLOGY. 128. p.62-65
Add to list
Analysis of DNA methylation in cancer : location revisited

Alexander Koch, Sophie C Joosten, Zheng Feng, Tim C de Ruijter, Muriel X Draht, Veerle Melotte, Kim M Smits, Jurgen Veeck, James G Herman, Leander Van Neste, et al.

(2018) NATURE REVIEWS CLINICAL ONCOLOGY. 15(7). p.459-466
Add to list
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics : a decision analytical model

Siebren Dijkstra, Tim M Govers, Rianne J Hendriks, Jack A Schalken, Wim Van Criekinge (UGent) , Leander Van Neste, Janneke PC Grutters, John P Michiel Sedelaar and Inge M van Oort

(2017) BJU INTERNATIONAL. 120(5). p.659-665
Add to list
Epigenetic risk score improves prostate cancer risk assessment

Leander Van Neste, Jack Groskopf, William E Grizzle, George W Adams, Mark S DeGuenther, Peter N Kolettis, James E Bryant, Gary P Kearney, Michael C Kearney, Wim Van Criekinge (UGent) , et al.

(2017) PROSTATE. 77(12). p.1259-1264
Add to list
- Conference Paper
- C3
Clinical performance of an epigenetic assay to identify occult high-grade prostate cancer in African American men

Leander Van Neste, Carlton Barnswell, Mark Jalkut, Ronald Tutrone, James Sylora, Ronald Anglade, Myron Murdock, Kelvin A Moses, Zvi Shiffman, Todd Vandenberg, et al.

(2017) JOURNAL OF UROLOGY. 197(4, suppl.). p.E128-E128
Add to list
A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients

Iris JH van Vlodrop, Sophie C Joosten, Tim De Meyer (UGent) , Kim M Smits, Leander Van Neste (UGent) , Veerle Melotte, Marcella MLL Baldewijns, Leo J Schouten, Piet A van den Brandt, Jana Jeschke, et al.

(2017) CLINICAL CANCER RESEARCH. 23(8). p.2006-2018
Add to list
Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria

Kim EM van Kessel, Leander Van Neste, Irene Lurkin, Ellen C Zwarthoff and Wim Van Criekinge (UGent)

(2016) JOURNAL OF UROLOGY. 195(3). p.601-607
Add to list
- Conference Paper
- C3
Identification of high-grade prostate cancer using urine-based molecular biomarkers combined with clinical risk factors

Leander Van Neste, Geert Trooskens (UGent) , Rianne J Hendriks, Jack Schalken and Wim Van Criekinge (UGent)

(2016) JOURNAL OF UROLOGY. 195(4, suppl.). p.E698-E698
Add to list
- Journal Article
- A1
- open access
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies

Leander Van Neste, Alan W Partin, Grant D Stewart, Jonathan I Epstein, David J Harrison and Wim Van Criekinge (UGent)

(2016) PROSTATE. 76(12). p.1078-1087
Add to list
- Conference Paper
- C3
Clinical utility of an epigenetic assay to reduce unnecessary repeat prostate biopsies

Jason Hafron, Thanh Huynh, Ayad S Khourdaji, Richard D Sante, Wim Van Criekinge (UGent) and Leander Van Neste

(2016) JOURNAL OF UROLOGY. 195(4, suppl.). p.E544-E544
Add to list
- Conference Paper
- C3
Ability of an epigenetic assay to identify anterior prostate tumors based on a negative 12-core biopsy

Todd Matthew Morgan, Simpa Samuel Salami, John Thomas Wei, Ganesh S Palapattu, Amy Gursky, Wim Van Criekinge (UGent) , Leander Van Neste and Rohit Mehra

(2016) JOURNAL OF CLINICAL ONCOLOGY. 34(2, suppl.).
Add to list
- Conference Paper
- C3
Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease

Leander Van Neste, Grant Stewart, Sandra Marlene Gaston, William E Grizzle, George W Adams, Gary P Kearney, Jonathan I Epstein, David James Harrison, Alan W Partin and Wim Van Criekinge (UGent)

(2016) In JOURNAL OF CLINICAL ONCOLOGY 34(2, suppl.).
Add to list
Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score

Leander Van Neste, Rianne J Hendriks, Siebren Dijkstra, Geert Trooskens (UGent) , Erik B Cornel, Sander A Jannink, Hans de Jong, Daphne Hessels, Frank P Smit, Willem JG Melchers, et al.

(2016) EUROPEAN UROLOGY. 70(5). p.740-748
Add to list
We are all individuals...: bioinformatics in the personalized medicine era

Leander Van Neste and Wim Van Criekinge (UGent)

(2015) CELLULAR ONCOLOGY. 38(1). p.29-37
Add to list
- Conference Paper
- C3
Risk stratification of aggressive prostate cancer based on combined epigenetic and clinical data of men with initial cancer-negative biopsies

Alan W Partin, Leander Van Neste, Grant D Stewart, Joseph Bigley, David J Harrison, Wim Van Criekinge (UGent) and Jonathan I Epstein

(2015) JOURNAL OF UROLOGY. 193(4, suppl.). p.E959-E960

Academic Bibliography

Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men

Analysis of DNA methylation in cancer : location revisited

Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics : a decision analytical model

Epigenetic risk score improves prostate cancer risk assessment

Clinical performance of an epigenetic assay to identify occult high-grade prostate cancer in African American men

A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients

Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria

Identification of high-grade prostate cancer using urine-based molecular biomarkers combined with clinical risk factors

Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies

Clinical utility of an epigenetic assay to reduce unnecessary repeat prostate biopsies

Ability of an epigenetic assay to identify anterior prostate tumors based on a negative 12-core biopsy

Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease

Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score

We are all individuals...: bioinformatics in the personalized medicine era

Risk stratification of aggressive prostate cancer based on combined epigenetic and clinical data of men with initial cancer-negative biopsies

Contents

Support

Contact